Key facts
- This page summarizes Stacy L. Taylor's Form 4 filing for Adaptive Biotechnologies Corp (ADPT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 23 Aug 2024, 16:27.
Stacy L. Taylor - 22 Aug 2024 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)
- Reporting relationship
- SVP and General Counsel
- Issuer ticker
- ADPT
- Reported as of
- 22 Aug 2024
- Net transaction value
- -$121,079
- SEC form
- 4
- Accepted by SEC
- 23 Aug 2024, 16:27:19 UTC
- Prior SEC filing
- 06 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stacy L Taylor
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stacy L. Taylor filed Form 4 for Adaptive Biotechnologies Corp (ADPT) on 23 Aug 2024.
Change
- Previous filing in this sequence was filed on 06 Mar 2024.
- Current net transaction value: -$121,079.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADPT
transaction
Common Stock
Sale
- Transaction value
- $121,079
- Shares
- -26,922
- Change %
- -16%
- Price
- $4.50
- Shares after
- 139,365
- Date
- 22 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 23, 2024.
Footnote F2
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $4.415 to $4.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.